Radius (RDUS) Announces Positive Data On Breast Cancer Drug
Zacks Investment Research | Jun 04, 2017 11:26PM ET
Radius Health, Inc. (NASDAQ:RDUS) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer.
RAD1901, an oral selective estrogen receptor degrader (SERD), is being evaluated for potential use as an oral non-steroidal treatment for estrogen receptor positive breast cancer at high doses.
Radius Health’s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date. The stock declined 7.7% compared with the industry’s gain of 5.7%.
As of the cut-off date of Apr 28, 2017, the fully enrolled study treated 40 patients at the 400 mg dose. The patients are all pretreated ER+, HER2-negative advanced breast cancer patients. The objective response rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer. In the 400 mg patient group with mature data, median PFS was 4.5 months and clinical benefit rate at 24 weeks was 42%. In fact, 38% of these patients previously received Faslodex, 40% received Ibrance (palbociclib) or another CDK inhibitor, 50% had an ESR1 mutation. It should be noted that 15 of the 40 patients remained on treatment as of the cut-off date.
Currently, Radius Health is evaluating RAD1901 in a phase I FES-PET study in patients with ER+, HER2-negative advanced breast cancerIn addition, the company entered a collaboration agreement with Novartis (NYSE:NVS) to explore RAD1901 in combination with Novartis’ LEE011 (Kisqali), a CDK 4/6 inhibitor, and BYL719 (alpelisib), an investigational phosphoinositide 3-kinase inhibitor.
Zacks Rank and Stocks to Consider
Radius Health carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include VIVUS, Inc. (NASDAQ:VVUS) and MEI Pharma, Inc. (NASDAQ:MEIP) sporting a Zacks Rank #1 (Strong Buy). You can see .
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Get The News You Want
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.